65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time After 6 Weeks — 369.81; 421.58; 420.72 seconds — p=0.0002
Kidney Stone
Primary: The Plasma and Urine Parameters — 6800; 6800; 3700; 3700 mg per dL
Coronary Artery Disease
Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1
Coronary Artery Disease
Primary: Major Adverse Cardiac Event (MACE) — 229 participants
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: PSA Response Rate With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer — 5 participants
Sleep Initiation and Maintenance Disorder; Elderly · Mental Disorder · Dyssomnias
Primary: Number of Participants Who Experience at Least One Adverse Event (AE) — 115; 116 Participants
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Parkinson's Disease · Depression · Anxiety
Primary: Most Commonly Reported Past Barrier to Mental Health Services: "Anyone in my Situation Would be Struggling" — 74.8 percentage of total respondents
Asthma
Primary: Number of Patients With Drug-related Adverse Events — 3; 6; 10 participants
Aging
Primary: Delay Eyeblink Conditioning — 52.32; 56.88 percentage of conditioned responses
Hypertension · Diabetes Mellitus, Type II
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6 — 6.79; 0.26 Percent HbA1c
Hypotension, Orthostatic
Primary: Orthostatic Hypotension at Discharge — 96 participants
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Tetraplegia · Asthma
Primary: Exhaled Levels of Nitric Oxide — 17.27; 19.83; 15.025; 3.70 ppb (parts per bilion)
Peripheral Arterial Disease
Primary: Successful Revascularization — 92.0 percentage of lesions — p=<0.05